CN100413492C - 口服给药治疗利什曼病的含有米替福星的固体药物组合物 - Google Patents

口服给药治疗利什曼病的含有米替福星的固体药物组合物 Download PDF

Info

Publication number
CN100413492C
CN100413492C CNB988125714A CN98812571A CN100413492C CN 100413492 C CN100413492 C CN 100413492C CN B988125714 A CNB988125714 A CN B988125714A CN 98812571 A CN98812571 A CN 98812571A CN 100413492 C CN100413492 C CN 100413492C
Authority
CN
China
Prior art keywords
pharmaceutical composition
mixture
flow control
miltex
described method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988125714A
Other languages
English (en)
Chinese (zh)
Other versions
CN1283111A (zh
Inventor
J·恩盖尔
W·萨利基奥提斯
T·克兰纳
P·海尔加德
D·萨尤尔比尔
E·米尔斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Asta Medica GmbH
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH, Zentaris AG filed Critical Asta Medica GmbH
Publication of CN1283111A publication Critical patent/CN1283111A/zh
Application granted granted Critical
Publication of CN100413492C publication Critical patent/CN100413492C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB988125714A 1998-01-22 1998-01-22 口服给药治疗利什曼病的含有米替福星的固体药物组合物 Expired - Fee Related CN100413492C (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (2)

Publication Number Publication Date
CN1283111A CN1283111A (zh) 2001-02-07
CN100413492C true CN100413492C (zh) 2008-08-27

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988125714A Expired - Fee Related CN100413492C (zh) 1998-01-22 1998-01-22 口服给药治疗利什曼病的含有米替福星的固体药物组合物

Country Status (24)

Country Link
US (1) US6544551B1 (enExample)
EP (1) EP1051159B1 (enExample)
JP (1) JP2002501015A (enExample)
KR (1) KR100517399B1 (enExample)
CN (1) CN100413492C (enExample)
AT (1) ATE215817T1 (enExample)
AU (1) AU756805B2 (enExample)
BR (1) BR9814772A (enExample)
CA (1) CA2318260C (enExample)
CZ (1) CZ299229B6 (enExample)
DE (1) DE69804865T2 (enExample)
DK (1) DK1051159T3 (enExample)
ES (1) ES2175663T3 (enExample)
HU (1) HUP0004363A3 (enExample)
IL (1) IL136196A (enExample)
NO (1) NO20003674L (enExample)
NZ (1) NZ505648A (enExample)
PL (1) PL189654B1 (enExample)
PT (1) PT1051159E (enExample)
SI (1) SI1051159T1 (enExample)
SK (1) SK284839B6 (enExample)
TR (1) TR200001717T2 (enExample)
UA (1) UA68372C2 (enExample)
WO (1) WO1999037289A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
UA82322C2 (uk) * 2002-07-30 2008-04-10 Центаріс Гмбх Застосування алкілфосфохолінів в комбінації з протипухлинними лікарськими засобами
DK1663197T3 (da) 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
SI1799196T1 (sl) 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
BR112013012652A2 (pt) 2010-11-22 2016-09-06 Dafra Pharma Res & Dev Bvba forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida
CN111298120A (zh) 2011-06-24 2020-06-19 格里生物公司 炎性病症的预防和治疗
EP2983709A1 (en) * 2013-04-08 2016-02-17 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
WO2016042372A1 (en) 2014-09-17 2016-03-24 Steer Engineering Private Limited Effervescent composition and method of making it
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
BR112021020389A2 (pt) * 2019-04-12 2021-12-07 Oblita Therapeutics Bvba Formulações de dosagem em comprimidos de oleil fosfocolina

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0534445A1 (de) * 1991-09-27 1993-03-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Herstellung eines Arzneimittels zur oralen oder topischen Verabreichung bei der Behandlung von Leishmaniasis
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
IE59778B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicament with anti-tumour action containing hexadecylphosphocholine
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
EP0419998A3 (en) * 1989-09-27 1991-10-23 Asta Pharma Aktiengesellschaft Use of alkylphosphonic acid derivatives for the treatment of psoriasis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0534445A1 (de) * 1991-09-27 1993-03-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Herstellung eines Arzneimittels zur oralen oder topischen Verabreichung bei der Behandlung von Leishmaniasis

Also Published As

Publication number Publication date
US6544551B1 (en) 2003-04-08
DK1051159T3 (da) 2002-08-05
EP1051159A1 (en) 2000-11-15
CA2318260A1 (en) 1999-07-29
NO20003674D0 (no) 2000-07-18
SK284839B6 (sk) 2005-12-01
DE69804865T2 (de) 2002-11-07
IL136196A (en) 2004-07-25
NZ505648A (en) 2002-10-25
SK9862000A3 (en) 2000-11-07
KR100517399B1 (ko) 2005-09-28
WO1999037289A1 (en) 1999-07-29
CN1283111A (zh) 2001-02-07
EP1051159B1 (en) 2002-04-10
ES2175663T3 (es) 2002-11-16
BR9814772A (pt) 2000-10-24
HUP0004363A2 (hu) 2001-04-28
TR200001717T2 (tr) 2000-11-21
PL342838A1 (en) 2001-07-16
CZ20002596A3 (cs) 2000-10-11
JP2002501015A (ja) 2002-01-15
PT1051159E (pt) 2002-09-30
HUP0004363A3 (en) 2002-12-28
PL189654B1 (pl) 2005-09-30
SI1051159T1 (en) 2002-10-31
KR20010034311A (ko) 2001-04-25
UA68372C2 (en) 2004-08-16
DE69804865D1 (de) 2002-05-16
AU6212198A (en) 1999-08-09
CZ299229B6 (cs) 2008-05-21
IL136196A0 (en) 2001-05-20
ATE215817T1 (de) 2002-04-15
AU756805B2 (en) 2003-01-23
NO20003674L (no) 2000-07-18
CA2318260C (en) 2006-11-21

Similar Documents

Publication Publication Date Title
ES2216244T3 (es) Composicion granular a base de simeticona y fosfato de calcio anhidro en forma de granulada.
US6544551B1 (en) Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis
CN1197554C (zh) 固体类脂制剂
DE60024491T2 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
EP0147741B1 (de) Pharmazeutische Zubereitung mit speziellen 1,2-Diacyl-Glycero-3-Phosphocholinen zur Behandlung von Erkrankungen im Magen-Darmbereich
EP0147735B1 (de) Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen
EP1651191B1 (en) Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use
AU709068B2 (en) Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid
AU2003236787B2 (en) Use of alkylphosphocholines for the preventative treatment of protozoan diseases
MXPA00005298A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
HK1033434A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
BG64968B1 (bg) Твърди фармацевтични състави, съдържащи милтефозин за орално приложение при лечението на leishmaniasis
KR20250071993A (ko) 용출률과 안정성이 향상된 밀크시슬 함유 경구 투여용 제제 및 그 제조방법
KR20190083770A (ko) 밀크시슬을 포함하는 용출율이 향상된 간 질환 예방 및 치료용 조성물
EP0465091B1 (en) Use of 3-oxygermylpropionic acid to treat cold syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ASTA MEDICA AG

Free format text: FORMER OWNER: ASTA DRUG COMPANY SHARES

Effective date: 20020109

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20020109

Address after: Frankfurt, Germany

Applicant after: Zentaris GmbH

Address before: Dresden

Applicant before: ASTA Pharma AG.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1033434

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee